PMID- 20064822
OWN - NLM
STAT- MEDLINE
DCOM- 20100507
LR  - 20141120
IS  - 1532-2092 (Electronic)
IS  - 1099-5129 (Linking)
VI  - 12
IP  - 3
DP  - 2010 Mar
TI  - The impact of statins and renin-angiotensin-aldosterone system blockers on 
      pulmonary vein antrum isolation outcomes in post-menopausal females.
PG  - 322-30
LID - 10.1093/europace/eup387 [doi]
AB  - AIMS: To assess whether treatment with statins or renin-angiotensin-aldosterone 
      system (RAAS) inhibitors as potential procedural 'augmenting agents' improved 
      atrial fibrillation (AF) catheter ablation recurrence rates in post-menopausal 
      females (PMFS). METHODS AND RESULTS: Five hundred and eighteen consecutive female 
      patients had undergone AF catheter ablation from January 2005 to May 2008. 
      Post-menopausal females were selected and procedure outcomes were compared 
      between cohorts of PMFS treated with statins or RAAS inhibitors to untreated 
      PMFS. Out of 408 PMFS, 36 (8.8%) were treated with a combination of RAAS 
      inhibitors and statins, thus were excluded leaving a total of 372 (91.2%) 
      patients in the study. Out of 372 patients, 111 (29.8%) were on statins (Group 
      1), 59 (15.9%) on RAAS inhibitors (Group 2), and 202 (54.3%) without RAAS 
      inhibitors or statins [(Group 3) control population]. Over a mean follow-up time 
      of 24 +/- 8.3 (median 25) months, 78 (70.6%) in Group 1, 38 (65.4%) in Group 2, 
      and 139 (68.8%) in Group 3 had procedural success. Statin or RAAS inhibitor use 
      did not predict lower recurrence rates [hazard ratio (HR): 1.26, P = 0.282 and 
      HR: 1.14, P = 0.728, respectively]. When compared with controls, no difference in 
      the cumulative incidence of recurrence was found with statin or RAAS inhibitors 
      use (P = 0.385 and P = 0.761, respectively). CONCLUSION: Treatment with statins 
      or RAAS inhibitors did not improve catheter ablation success rates among PMFS. 
      Thereby, from a clinical standpoint, PMFS should not be started on these 
      treatments as a procedural 'augmenting agent' at this time.
FAU - Patel, Dimpi
AU  - Patel D
AD  - St David's Medical Center, Texas Cardiac Arrhythmia Institute, Austin, TX, USA.
FAU - Mohanty, Prasant
AU  - Mohanty P
FAU - Di Biase, Luigi
AU  - Di Biase L
FAU - Wang, Yan
AU  - Wang Y
FAU - Shaheen, Mazen H
AU  - Shaheen MH
FAU - Sanchez, Javier E
AU  - Sanchez JE
FAU - Horton, Rodney P
AU  - Horton RP
FAU - Gallinghouse, G Joseph
AU  - Gallinghouse GJ
FAU - Zagrodzky, Jason D
AU  - Zagrodzky JD
FAU - Bailey, Shane M
AU  - Bailey SM
FAU - Burkhardt, J David
AU  - Burkhardt JD
FAU - Lewis, William R
AU  - Lewis WR
FAU - Diaz, Alberto
AU  - Diaz A
FAU - Beheiry, Salwa
AU  - Beheiry S
FAU - Hongo, Richard
AU  - Hongo R
FAU - Al-Ahmad, Amin
AU  - Al-Ahmad A
FAU - Wang, Paul
AU  - Wang P
FAU - Schweikert, Robert
AU  - Schweikert R
FAU - Natale, Andrea
AU  - Natale A
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
DEP - 20100110
PL  - England
TA  - Europace
JT  - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal 
      of the working groups on cardiac pacing, arrhythmias, and cardiac cellular 
      electrophysiology of the European Society of Cardiology
JID - 100883649
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
CIN - Europace. 2010 Mar;12(3):299-300. PMID: 20173204
MH  - Aged
MH  - Angiotensin II Type 1 Receptor Blockers/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy/epidemiology/*surgery
MH  - C-Reactive Protein/metabolism
MH  - Catheter Ablation/*methods/statistics & numerical data
MH  - Combined Modality Therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Kaplan-Meier Estimate
MH  - Middle Aged
MH  - Postmenopause
MH  - Postoperative Complications/epidemiology/prevention & control
MH  - Predictive Value of Tests
MH  - Proportional Hazards Models
MH  - Renin-Angiotensin System/drug effects
MH  - Risk Factors
MH  - Secondary Prevention
MH  - Treatment Outcome
EDAT- 2010/01/13 06:00
MHDA- 2010/05/08 06:00
CRDT- 2010/01/13 06:00
PHST- 2010/01/13 06:00 [entrez]
PHST- 2010/01/13 06:00 [pubmed]
PHST- 2010/05/08 06:00 [medline]
AID - eup387 [pii]
AID - 10.1093/europace/eup387 [doi]
PST - ppublish
SO  - Europace. 2010 Mar;12(3):322-30. doi: 10.1093/europace/eup387. Epub 2010 Jan 10.